PDCD1 and lung carcinoma: In a mouse model of lung cancer, the administration of low doses of apatinib, a VEGFR2 tyrosine kinase inhibitor (TKI), in combination with anti-PD-1 mAbs was shown to exert a positive impact on inhibiting tumor progression [56].